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Cardiac risk stratification in patients undergoing
endoluminal graft repair of abdominal aortic
aneurysm: A single-institution experience with
365 patients
Ihab N. Aziz, MD, Jason T. Lee, MD, George E. Kopchok, BS, Carlos E. Donayre, MD,
Rodney A. White, MD, and Christian de Virgilio, MD, Torrance, Calif
Objective: Patients undergoing abdominal aortic aneurysm repair have a high incidence of coexisting cardiac disease. The
traditional cardiac risk stratification for open abdominal aortic aneurysm surgery may not apply to patients undergoing
endoluminal graft exclusion. The purpose of this study was to examine predictive risk factors for perioperative cardiac
events.
Methods: As part of multiple prospective endograft trials approved by the US Food and Drug Administration, data for 365
patients who underwent endoluminal graft repair from 1996 to 2001 were collected. Variables included for analysis were
age and sex; history of smoking; presence of hypertension, diabetes mellitus, or renal insufficiency; Eagle clinical cardiac
risk factors; American Society of Anesthesiologists index; type of anesthesia administered; estimated blood loss;
preoperative hemoglobin level; preoperative use of -blocker therapy; duration of surgery; need for iliac artery conduit;
and concomitant other vascular procedures. Univariate and multivariate logistic regression analysis were used to
determine which variables were predictive of an adverse perioperative cardiac event, eg, Q wave and non–Q wave
myocardial infarction (MI), congestive heart failure (CHF), severe arrhythmia, and unstable angina.
Results: The study cohort included 322 men and 43 women (mean age, 74.2 years). Fifty-two (14.2%) postoperative
cardiac events occurred: severe dysrhythmia in 15 patients (4.1%), MI in 14 patients (3.8%), non–Q wave MI in 8 patients
(2.2%), CHF in 8 patients (2.2%), and unstable angina in 7 patients (1.9%). Univariate analysis demonstrated that age 70
years or older (P  .034), history of MI (P  .018), angina (P  .004), history of CHF (P < .001), two or more Eagle
risk factors (P < .001), and lack of use of preoperative -blocker therapy (P  .005) were predictors of perioperative
cardiac events. Multivariate analysis identified only age 70 years or older (P  .026), history of MI (P  .024) or CHF
(P .001), and lack of use of preoperative -blocker therapy (P .007) as independent risk factors for an adverse cardiac
event.
Conclusions: Age 70 years or older, history of MI or CHF, and lack of use of preoperative -blocker therapy are
independent risk factors for perioperative cardiac events in patients undergoing endoluminal graft repair. (J Vasc Surg
2003;38:56-60.)
Increased demand for less invasive surgery has resulted
in the emergence of endoluminal graft repair of abdominal
aortic aneurysm (AAA) as an alternative to open abdominal
repair. Several studies have reported the feasibility and
potentially low operative morbidity of this less invasive
procedure,1-4 even in patients at high risk.5
Open AAA repair is associated with 4% to 10% mortal-
ity.6-10 These mortality rates have been challenged recently
in the Aneurysm Detection and Management (ADAM)
trial from the United States, with only 2.7% overall opera-
tive mortality rate.11 Coronary artery disease is the most
prominent risk factor, accounting for up to 60% of periop-
erative deaths.7,8,12-14 This proportionately high cardiac
morbidity can be explained by several factors. Angiographic
studies have shown that 60% of patients with AAA have
severe coronary artery disease.15 Perioperative myocardial
stress is exacerbated by the depressant effects of anesthetics,
cross clamping of the aorta, blood loss, and associated
hemodynamic and metabolic changes.16,17
Risk stratification for cardiac events after open AAA
repair has been studied by numerous authors.18-25 Fewer
data are available for risk stratification after endoluminal
graft repair. Most studies to date suggest that cardiac
morbidity and overall mortality for open and endoluminal
graft repair are comparable.1,2,4,26 Nevertheless, differ-
ences in stratification may exist, because endoluminal graft
repair may impose less myocardial and hemodynamic stress
than with open AAA repair. The purpose of this study was
to determine which preoperative and operative variables
were predictive of perioperative cardiac events.
METHODS
Study patients included those enrolled in one of multi-
ple prospective trials approved by the US Food and Drug
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Administration (FDA) and those who underwent surgery
after FDA approval. The procedures were performed at our
institution from June 1996 through June 2001, and in-
cluded Phase I (n  24), Phase II (n  74), and Phase III
(n  91) trials of the AneuRx bifurcated prosthesis
(Medtronic AVE, Santa Rosa, Calif); Phase I (n  46) of
the Talent bifurcated prosthesis (Medtronic World Medi-
cal, Sunrise, Fla); and Phase I (n 9) and Phase II (n 25)
of the Endologix bifurcated device (Endologix, Phoenix,
Ariz). Data for 96 procedures in which the AneuRx device
was placed post-FDA approval were also included in the
analysis. Patients were enrolled in a protocol approved by
the Institutional Review Board of our medical center, and
signed consent forms were obtained for the investigational
devices and the postoperative imaging surveillance proto-
cols.
The data were prospectively entered into a database,
and the records for these 365 consecutive patients (322
men, 43 women; mean age, 74.2  8.57 years) were
reviewed for this study. Variables examined included age
and sex; history of smoking; presence of hypertension,
diabetes mellitus, or renal insufficiency; clinical cardiac risk
factors as described by Eagle et al,27 ie, diabetes, age older
than 70 years, angina, previous myocardial infarction (MI)
by history or by Q wave on electrocardiogram (ECG), and
history of congestive heart failure (CHF); American Society
of Anesthesiologists index; type of anesthetic administered;
estimated blood loss; preoperative hemoglobin level; pre-
operative -blocker therapy; duration of surgery; need for
iliac artery conduit; concomitant other vascular procedures;
and postoperative cardiac events.
Perioperative cardiac complications were defined as
occurring within 30 days of surgery or during the hospital
admission. Cardiac events were defined as Q wave and
non–Q wave MI, CHF, unstable angina, ventricular ar-
rhythmia, heart block, and cardiac death. MI was defined as
including two or more of the following criteria: cardiac
enzyme levels more than 5% or troponin concentration
greater than 1.3, ECG ischemic changes, or chest pain for
more than 30 minutes. Non–Q wave MI was defined as
elevated cardiac enzyme levels with no ECG changes. As a
routine part of the studies protocol, creatine kinase–MB
and troponin concentrations, and ECG were obtained ev-
ery 8 hours for the first 24 hours; all patients underwent the
same postoperative screening to avert missed silent MI.
CHF was defined as symptoms or signs of pulmonary
edema or of right or left ventricular failure, and abnormal
chest x-ray. Ventricular tachycardia was defined as prema-
ture ventricular contractions lasting for more than 30 sec-
onds, more than 30 beats, and resulting in hemodynamic
compromise. Unstable angina was defined as typical chest
pain lasting for more than 30 minutes and relieved by rest
or nitroglycerine. Renal insufficiency was defined as preop-
erative serum creatinine concentration greater than 1.5
mg/dL. Routine preoperative cardiac stress testing was not
performed in the study patients.
The 365 patients were divided into two groups, 52
patients with a postoperative cardiac event and 313 who did
not sustain a postoperative cardiac event. Variables were
compared between the two groups to establish predictors
of cardiac events with 2 or Fisher exact test, where appro-
priate. Continuous variables were compared with the Wil-
coxon rank-sum test. Variables found to be significant at
univariate analysis were entered into a multivariate logistic
regression analysis. P  .05 was considered statistically
significant. All statistical analysis was performed with Systat
8.0 for Windows (SPSS Inc, Chicago, Ill).
RESULTS
Data for 365 patients (322 men, 43 women; mean age,
74.2 years) were included in the analysis. Patient demo-
graphic data and comorbid conditions are shown in Table I.
The most frequent clinical cardiac risk factor was age older
than 70 years, present in 72% of patients. There were 52
(14.2%) postoperative cardiac events, including MI in 14
patients (3.8%), arrhythmia in 12 patients (3.3%), non–Q
wave MI in 8 patients (2.2%), CHF in 8 patients (2.2%),
angina in 7 patients (1.9%), and heart block in 3 patients
(0.8%). Univariate analysis demonstrated that age 70 years
or older (P .034), history of MI (P .018), angina (P
.004), history of CHF (P  .001), two or more Eagle risk
factors (P  .001), and lack of use of preoperative
-blocker therapy (P  .005) were predictors of postoper-
ative cardiac events (Table II). Cardiac event rate by num-
ber of Eagle risk factors is presented in Table III. On the
other hand, preoperative hemoglobin and serum creatinine
concentrations, American Society of Anesthesiologists
score, operative time, type of device used, gender, need for
placement of a conduit, concomitant vascular procedure,
diabetes, hypertension, preoperative renal insufficiency,
history of smoking, type of anesthetic administrered, and
number of stents used were not predictive of postoperative
cardiac events. At multivariate analysis, only age 70 years or
older (P .032), history of MI (P .025), history of CHF
(P  .002), and lack of use of preoperative -blocker
therapy (P  .027) were independent risk factors for a
postoperative cardiac event. Table IV shows the odds ratios
for the various independent risk factors.
The cardiac event rate based on the number of inde-
pendent risk factors present is listed in Table V. The cardiac
event rate for patients with four risk factors was 50%,
compared with 5.3% in patients with no risk factors.
Table I. Preoperative data for 365 patients
Factor n %
Male gender 322 88
Age 70 263 72
Smoking status 193 53
History of myocardial infarction 75 20
Diabetes mellitus 49 13
Chronic renal failure 22 6
Congestive heart failure 33 9
Angina 37 10
History of hypertension 218 60
Preoperative -blocker therapy 243 67
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Ten patients (2.7%) died in the first postoperative 30
days or during the hospital stay. Cardiac events were the
direct cause of death in 4 patients (1.1%). The presence of
two or more Eagle risk factors (P  .002) and need for
concomitant vascular procedure (P  .003) were the only
variables predictive of cardiac death.
DISCUSSION
Endoluminal graft repair of AAA is a less invasive
technique than standard open repair and is thus theoreti-
cally appealing in patients at high risk. This is supported by
studies that demonstrate that endoluminal graft repair is
less hemodynamically stressful than open repair. Cuypers et
al28 reported that open repair caused a greater decrease in
systemic vascular resistance as compared with endoluminal
graft repair. Stroke work index, a measure of myocardial
performance, diminished when the aorta was occluded
during open repair and increased during endoluminal graft
repair. Despite the less severe hemodynamic changes asso-
ciated with endoluminal graft repair, postoperative clinical
cardiac complications were the same for both endoluminal
graft and open repair.29-30 Similarly, de Virgilio et al26
found no difference in cardiac complication rates or mor-
tality when comparing endoluminal graft repair with open
repair. In the present study cardiac morbidity was 14.2%.
This relatively high morbidity rate may be due to our
definition of cardiac events, which is broader and more
inclusive than that of other studies. Overall mortality was
2.7%, whereas cardiac mortality was only 1.1%. This mor-
tality rate is at the low end of the range of published cardiac
mortality rates for open repair (2.7%-10%).6-11
The less invasive nature of endoluminal graft repair
would suggest that standard methods for cardiac risk strat-
ification might not be applicable. Although cardiac risk
stratification for open AAA repair has been studied exten-
sively,21-24 fewer data are available for endoluminal graft
repair. The present study confirms the utility of clinical
cardiac risk factors (age 70 years, history of MI or CHF)
as independent predictors of adverse perioperative cardiac
events. Previous MI or CHF is an important clinical pre-
dictor of cardiac morbidity after endoluminal graft repair.25
Other variables, including female gender and elevated
serum creatinine concentration, are important predictors of
mortality after open AAA repair. Katz et al31 showed that
mortality in female patients undergoing open repair are
higher than in male patients. Crawford et al32 and Dardik et
al33 reported similar results. This concept was challenged
by Johnston et al,34 Wolf et al,35 and Mathison et al,36 who
showed no difference in postoperative overall mortality or
complications between male and female patients. In the
present study we found no difference in rate of cardiac
events between men (13%) and women (21%) (P  .182).
Similarly, in another study34 serum creatinine value was a
predictor of outcome; in the present study, mean serum
creatinine concentration in patients with cardiac events
(1.34 mg/dL) was not different from that in patients
without cardiac events (1.28 mg/dL; P  .32). However,
the low frequency of both variables might have created a
statistical error in this study.
While multiple reports27,38 proposed use of clinical
markers for cardiac risk stratification, others39,40 have ar-
Table II. Univariate analysis of cardiac events
Variable
Cardiac
events
(n  52)
No cardiac
events
(n  313)
Pn % n %
Female gender 9 17 34 11 .182
Age 70 44 85 219 70 .034
History of MI 17 33 58 18 .018
Angina 11 21 26 8 .004
History of CHF 12 23 21 7 .001
Diabetes mellitus 8 15 41 13 .647
Hypertension 30 58 188 60 .764
Renal insufficiency 5 10 17 5 .237
Smoking 28 54 165 53 .728
Lack of use of -blocker 17 33 52 17 .005
Use of conduit 1 2 7 2 .87
Concomitant vascular
procedure
12 23 47 15 .153
MI, Myocardial infarction; CHF, congestive heart failure.
Table III. Cardiac events by number of Eagle risk
factors*
Number of Eagle criteria
Cardiac events
n %
0 3/59 5.1
1 20/187 10.7
2 19/85 22
3 12/19 63
4 6/9 66
5 1/1 100
Total 52/360 14.4
*P  .001.
Table IV. Odds ratio for independent risk factors
Odds ratio
95% confidence
interval P
Age 70 1.65 1.05-2.59 .026
Myocardial infarction 1.58 1.06-2.36 .024
Congestive heart failure 2.22 1.35-3.65 .001
Lack of use of -blockers 1.53 1.05-2.04 .007
Table V. Cardiac event rate by number of risk factors
No. of
risk factors
Patients
(N  365)
Cardiac event
rate (%)
0 19 5.3
1 116 10.3
2 188 12.2
3 38 36.8
4 4 50.0
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gued that clinical assessment alone fails to detect significant
coronary artery disease in patients unable to exercise and
fails to predict cardiac events.
In our two previous studies,41,42 we found that no
individual Eagle criterion was predictive of adverse cardiac
events in patients undergoing major elective vascular sur-
gery. In a more recent study that focused on patients
undergoing open and endoluminal graft repair of AAA,
history of CHF and Q wave on ECG were the only Eagle
criteria predictive of postoperative cardiac events.26 The
present study confirmed the importance of age older than
70 years and history of MI or CHF as independent predic-
tors for cardiac events (Table II). The study also demon-
strates a stepwise increase in cardiac risk as the number of
risk factors increases (Table V).
Perioperative use of -blockers reduces the incidence of
cardiac complications after major vascular surgery.43-46 In a
randomized study of patients at high cardiac risk (positive
dobutamine ECG and 1 or more Eagle risk factors) under-
going major vascular surgery, Poldermans et al45 demon-
strated that use of bisoprolol significantly reduced the rate
of nonfatal perioperative MI from 17% to 0% and reduced
cardiac mortality from 17% to 3.4%, when compared with
patients not receiving a -blocker. The role of perioperative
-blockade for patients undergoing endoluminal graft re-
pair of AAA is not well defined. Given the less invasive
nature of endoluminal graft repair and studies demonstrat-
ing that this procedure causes less hemodynamic stress, one
might expect a lack of benefit to adding -blockade in these
patients. In the present study, 243 patients (67%) were
receiving -blockers preoperatively; only 27 patients
(11.1%) had cardiac events, compared with 17 of 69 pa-
tients (24.6%) who did not receive preoperative -blocker
therapy (P  .004). Significantly, at multivariate analysis
the lack of perioperative -blockade was an independent
predictor for an adverse cardiac event.
The role of cardiac risk assessment and coronary revas-
cularization before major vascular surgery remains contro-
versial. Our current practice is to strictly limit cardiac stress
testing and coronary revascularization to patients with re-
cent or severe cardiac symptoms. This approach is sup-
ported by the overall low cardiac mortality (1.1%) reported
in this series. However, given the high cardiac event rate
noted in this study for patients with multiple risk factors
(history of MI or CHF, and age older than 70 years),
consideration should be given to stress testing in this highly
selected subgroup of patients.
In conclusion, the present study reports 14.2% cardiac
morbidity, 1.1% cardiac mortality, and 2.7% overall mortal-
ity in a series of 365 consecutive patients undergoing
endoluminal graft repair of AAA. The study confirmed the
importance of the presence of multiple clinical risk factors
(history of MI or CHF, age older than 70 years) as predic-
tors of adverse cardiac events. Furthermore, the study
demonstrated that use of perioperative -blockade is im-
portant during endoluminal graft repair, although this pro-
cedure is less hemodynamically stressful than open repair.
For patients with multiple cardiac risk factors, it is yet to be
determined whether the addition of -blockade is sufficient
cardiac protection or whether additional cardiac stress test-
ing with coronary revascularization is needed.
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